By Professor Sean Emery

Journal articles

Yeni PG; Cooper DA; Aboulker J; Babiker AG; Carey DL; Darbyshire JH; Floridia M; Girard P; Goodall R; Hooker M; Mijch AM; Meiffredy V; Salzberger B, 2006, 'Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial.', Lancet, 368, pp. 287 - 298

Emery SB; Hubbley JL; Darling MA; Roy D, 2005, 'Chemical factors for chemical-mechanical and electrochemical-mechanical planarization of silver examined using potentiodynamic and impedance measurements', MATERIALS CHEMISTRY AND PHYSICS, 89, pp. 345 - 353, http://dx.doi.org/10.1016/j.matchemphys.2004.09.011

Sabik L; Pace CA; Forster-Gertner HP; Wendler D; Bebchuk JD; Tavel JA; McNay LA; Killen J; Emanuel EJ; Grady C, 2005, 'Informed consent: Practices and views of investigators in a multinational clinical trial', IRB Ethics and Human Research, 27, pp. 13 - 18, http://dx.doi.org/10.2307/3564530

Wand HC; Law MG; Emery S; Cooper DA; Carr AD, 2005, 'Increase in limb fat after nucleoside analogue cessation is not associated with decreased visceral fat and has different risk factors', Antiviral Therapy, 10, pp. L5 - L5, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000235133100020&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Winters B; Harrigan R; Montaner JS; Perez-Elias M; Miller M; Emery S; van Leth F; Robinson P; Baxter J; Gazzard B; Pozniak A; Castor D; Hammer S; Rinehart A; Bacheler L, 2005, 'Clinically relevant breakpoints for virco (R) TYPE HIV-1 phenotypic resistance information', Antiviral Therapy, 10, pp. S39 - S39, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000231963100053&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Winston A; Bloch MT; Carr AD; Amin J; Mallon PW; Ray J; Marriott D; Cooper DA; Emery S, 2005, 'Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy', Journal of Antimicrobial Chemotherapy, 56, pp. 380 - 387

Mallon PW; Wand HC; Law MG; Miller J; Cooper DA; Carr AD, 2005, 'Buffalo hump seen in HIV-associated lipodystrophy is associated with hyperinsulinemia but not dyslipidemia.', JAIDS: Journal of Acquired Immune Deficiency Syndromes, 38, pp. 156 - 162, http://journals.lww.com/jaids/Fulltext/2005/02010/Buffalo_Hump_Seen_in_HIV_Associated_Lipodystrophy.6.aspx

Carey DL; Wand HC; Martin A; Rothwell S; Emery S; Cooper DA; Carr AD, 2005, 'Evaluation of ultrasound for assessing facial lipoatrophy in a randomized, placebo-controlled trial', AIDS, 19, pp. 1325 - 1327

Duncombe CJ; Kerr SJ; Ruxrungtham K; Dore GJ; Law MG; Emery S; Lange J; Phanuphak P; Cooper DA, 2005, 'HIV disease progression in a patient cohort treated via a clinical research network in a resource limited setting', AIDS, 19, pp. 169 - 178

Mallon PW; Unemori P; Sedwell R; Morey AL; Rafferty M; Williams KM; Chisholm DJ; Samaras K; Emery S; Kelleher AD; Cooper DA; Carr AD, 2005, 'In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA', Journal of Infectious Diseases, 191, pp. 1686 - 1696

Kovacic JC; Martin A; Carey DL; Wand HC; Mallon PW; Feneley MP; Emery S; Cooper DA; Carr AD, 2005, 'Influence of rosiglitazone on flow-mediated dilation and other markers of cardiovascular risk in HIV-infected patients with lipoatrophy', Antiviral Therapy, 10, pp. 135 - 143

Emery S; Workman C; Puls R; Bloch M; Baker D; Bodsworth NJ; Anderson JA; Crowe SM; Hoy JF; Aichelburg A; Ward LA; Boyle D; Law MG; Kelleher AD; Cooper DA, 2005, 'Randomised, Placebo-Controlled, Phase 1/2a Evaluation of the Safety and Immunogenicity of Fowlpox Virus Expressing HIV gag-pol and Interferon-y in HIV-1 Infected Subjects', Human Vaccines, 1, pp. 232 - 238, http://www.landesbioscience.com/journals/vaccines/emeryHV1-6.pdf

Winston A; Hales GP; Amin J; van Schaick E; Cooper DA; Emery S, 2005, 'The normalized inhibitory quotient of boosted protease inhibitors is predictive of viral load response in treatment-experienced HIV-1-infected individuals', AIDS, 19, pp. 1393 - 1399

Pace C; Emanuel EJ; Chuenyam T; Duncombe C; Bebchuk JD; Wendler D; Tavel JA; McNay LA; Phanuphak P; Forster HP; Grady C, 2005, 'The quality of informed consent in a clinical research study in Thailand.', IRB, 27, pp. 9 - 17, https://www.ncbi.nlm.nih.gov/pubmed/15835065

McClelland RS; Baeten JM; Overbaugh J; Richardson BA; Mandaliya K; Emery S; Lavreys L; Ndinya-Achola JO; Bankson DD; Bwayo JJ; Kreiss JK, 2004, 'Micronutrient supplementation increases genital tract shedding of HIV-1 in women - Results of a randomized trial', JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 37, pp. 1657 - 1663, http://dx.doi.org/10.1097/00126334-200412150-00021

Pett SL; Williams LA; Day RO; Lloyd AR; Carr AD; Clezy KR; Emery S; Kaplan E; Mcphee D; Mclachlan AJ; Gelder F; Lewin S; Liauw WS; Williams KM, 2004, 'A phase I study of the pharmacokinetics and safety of passive immunotherapy with caprine anti-HIV antibodies, (PE)HRG214, in HIV-1-infected individuals', HIV Clinical Trials, 5, pp. 91 - 98

Arduino R; Nannini E; Rodriguez-Barradas M; Schrader S; Losso MH; Ruxrungtham K; Allende MC; Emery S; Fosdick L; Neaton JD; Tavel JA; Davey R; Lane HC, 2004, 'CD4 cell response to 3 doses of subcutaneous interleukin 2:Meta-analysis of 3 Vanguard studies', Clinical Infectious Diseases, 39, pp. 115 - 122

Mallon PW; Sedwell R; Unemori P; Rafferty M; Williams KM; Chisholm DJ; Samaras K; Emery S; Kelleher AD; Cooper DA; Carr AD, 2004, 'Changes in nuclear gene expression resulting from NRTI-induced inhibition of mitochondrial transcription reveal links between mitochondrial dysfunction and lipid metabolism', Antiviral Therapy, 9, pp. L56 - L56

Dale C; De Rose R; Wilson K; Croom H; Thomson S; Coupar B; Ramsay AJ; Purcell D; Ffrench R; Law MG; Emery S; Cooper DA; Ramshaw I; Boyle D; Kent S, 2004, 'Evaluation in macaques of HIV-1 DNA vaccines containing primate CpG motifs and fowlpoxvirus vaccines co-expressing IFN[gamma] or IL-12', Vaccine, 23, pp. 188 - 197, http://www.sciencedirect.com/science/article/B6TD4-4CN9FR0-5/2/aa9e52964e8dec8ad797d2f13a3a639e

Mallon PW; Unemori P; Sedwell R; Morey AL; Rafferty M; Williams KM; Chisholm DJ; Samaras K; Emery S; Kelleher AD; Cooper DA; Carr AD, 2004, 'In vivo nucleoside reverse transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes independent to HIV infection', Antiviral Therapy, 9, pp. L11 - L11

Carr AD; Workman C; Carey DL; Rogers GJ; Martin A; Baker DA; Wand HC; Law MG; Samaras K; Emery S; Cooper DA, 2004, 'No effect of rosiglitazone for treatment of HIV-1 lipoatrophy:randomised, double-blind, placebo-controlled trial', Lancet, 363, pp. 429 - 438, http://dx.doi.org/10.1016/S0140-6736(04)15489-5

Martin A; Smith DE; Carr AD; Ringland C; Amin J; Emery S; Hoy JF; Workman C; Doong N; Freund J; Cooper DA, 2004, 'Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study', AIDS, 18, pp. 1029 - 1036, http://www.medscape.com/viewarticle/474870

Carey DL; Workman C; Rogers GJ; Baker DA; Martin A; Wand HC; Emery S; Cooper DA; Carr AD, 2004, 'Rosiglitazone for HIV lipoatrophy: 84 weeks follow-up', Antiviral Therapy, 9, pp. L46 - L46

Ungsedhapand C; Srasuebkul P; Cardiello P; Ruxrungtham K; Ratanasuwan W; Kroon E; Tongtalung M; Juengprasert N; Ubolyam S; Siangphoe U; Emery S; Lange JM; Cooper DA; Phanuphak P, 2004, 'Three-year durability of dual-nucleoside versus triple-nucleoside therapy in a Thai population with HIV infection', JAIDS: Journal of Acquired Immune Deficiency Syndromes, 36, pp. 693 - 701

Sirivichayakul S; Ruxrungtham K; Ungsedhapand C; Techasathit W; Ubolyam S; Chuenyam T; Emery S; Cooper D; Lange J; Phanuphak P, 2003, 'Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitors', AIDS, 17, pp. 1889 - 1896, http://dx.doi.org/10.1097/00002030-200309050-00007

Amin J; Moore A; Carr A; French MA; Law M; Emery S; Cooper DA, 2003, 'Combined Analysis of Two-Year Follow-Up from Two Open-Label Randomized Trials Comparing Efficacy of Three Nucleoside Reverse Transcriptase Inhibitor Backbones for Previously Untreated HIV-1 Infection: OzCombo 1 and 2', HIV Research & Clinical Practice, 4, pp. 252 - 261, http://dx.doi.org/10.1310/hct.2003.4.4.004

Sayer DC; Land S; Gizzarelli L; French M; Hales G; Emery S; Christiansen FT; Dax EM; Dunne M; Crowe S; Birch C; Middleton T; Saksena N; Bryson G; Salem H; Cunningham P; Suzuki K; Schroeder B; Rawlings L; Higgins G; Chuah J; Roth N; Barnes T; Mills G; Daye J; Watson J, 2003, 'Quality assessment program for genotypic antiretroviral testing improves detection of drug resistance mutations', Journal of Clinical Microbiology, 41, pp. 227 - 236, http://dx.doi.org/10.1128/JCM.41.1.227-236.2003

Carr AD; Emery S; Law MG; Puls R; Lundgren JD; Powderly W, 2003, 'An objective case definition of lipodystrophy in HIV-infected adults: a case-control study', Lancet, 361, pp. 726 - 735

Carr AD; Law MG, 2003, 'An objective lipodystrophy severity grading scale using the lipodystrophy case definition score', Journal of Acquired Immune Deficiency Syndrome, 33, pp. 571 - 576

Clegg AO; Williamson P; Biti RA; Cooper DA; Emery S; Carr AD; Stewart GJ, 2003, 'Chemokine receptor genotype and response to interleukin-2 therapy in HIB-1-infected individuals', Clinical Immunology, 106, pp. 36 - 40

Amin J; Moore A; Carr AD; French MA; Law MG; Emery S; Cooper DA, 2003, 'Combined analysis of two-year follow-up from two open-label randomized trials comparing efficacy of three nucleoside reverse transcriptase inhibitor backbones for previously untreated HIV-1 infection: OzCombo 1 and 2', HIV Clinical Trials, 4, pp. 252 - 261

Ioannidis JP; Trikalinos TA; Law MG; Carr AD, 2003, 'HIV lipodystrophy case definition using artificial neural network modelling.', Antiviral Therapy, 8, pp. 435 - 441

Miller J; Carr AD; Emery S; Law MG; Mallal SS; Baker D; Smith DG; Kaldor JM; Cooper DA, 2003, 'HIV lipodystrophy: prevalence, severity and correlates of risk in Australia', HIV Medicine, 4, pp. 293 - 301

Birch C; Middleton T; Hales GP; Cooper DA; Law MG; Crowe S; Hoy JF; Emery S, 2003, 'Limited evolution of HIV antiretroviral drug resistance-associated mutations during the performance of drug resistance testing', Journal of Acquired Immune Deficiency Syndrome, 32, pp. 57 - 61

Law MG; Emery S, 2003, 'Selective exclusion of treatment arms in multi-arm randomized clinical trials', Statistics in Medicine, 22, pp. 19 - 30

Panteleeff DD; Emery S; Richardson BA; Rousseau C; Benki S; Bodrug S; Kreiss JK; Overbaugh J, 2002, 'Validation of performance of the Gen-Probe human immunodeficiency virus type 1 viral load assay with genital swabs and breast milk samples', JOURNAL OF CLINICAL MICROBIOLOGY, 40, pp. 3929 - 3937, http://dx.doi.org/10.1128/JCM.40.11.3929-3937.2002

French M; Amin J; Roth N; Carr A; Law M; Emery S; Drummond F; Cooper D; investigators* OBOO2, 2002, 'Randomized, open-Label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: The OzCombo 2 study', HIV Research & Clinical Practice, 3, pp. 177 - 185, http://dx.doi.org/10.1310/hct.2002.3.3.001

McNay LA; Tavel JA; Oseekey K; McDermott CM; Mollerup D; Bebchuk JD, 2002, 'Regulatory approvals in a large multinational clinical trial: the ESPRIT experience', CONTROLLED CLINICAL TRIALS, 23, pp. 59 - 66, http://dx.doi.org/10.1016/S0197-2456(01)00183-0

Emery S; Birch C; Crowe S; Hoy J; Workman C; Kelleher T; McKenna P; Cooper D; Lincoln D; Hales G; Law M, 2002, 'CREST - A randomised comparison of two resistance test platforms: genotype and genotype plus VirtualPhenotype (TM): interim results', ANTIVIRAL THERAPY, 7, pp. S152 - S152, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000177401300141&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Emery S; Cooper DA, 2002, 'HIV medicine', Medical Journal of Australia, 176, pp. 21 - 21

French MA; Amin J; Roth N; Law MG; Emery S; Drummond F, 2002, 'Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 infection: The OzCombo 2 Study', HIV Clinical Trials, 3, pp. 177 - 185

Emery S; Abrams D; Cooper DA; Darbyshire JH; Lane HC; Lundgren JD; Neaton JD, 2002, 'The evaluation of subcutaneous proleukin® (interleukin-2) in a randomized international trial: rationale, design, and methods of ESPRIT. Control Clin Trials', Control Clin Trials, 23, pp. 198 - 220

Pett SL; Emery S, 2001, 'Immunomodulators as adjunctive therapy for HIV-1 infection', Journal of Clinical Virology, 22, pp. 289 - 295, http://dx.doi.org/10.1016/S1386-6532(01)00201-3

Tavel JA; Fosdick L, 2001, 'Closeout of four phase II Vanguard trials and patient rollover into a large international phase III HIV clinical endpoint trial', Controlled Clinical Trials, 22, pp. 42 - 48, http://dx.doi.org/10.1016/S0197-2456(00)00114-8

Emery S; Lane HC; Neaton JD, 2001, 'Interleukin-2 in clinical trials: Other factors to be considered - Reply', JOURNAL OF INFECTIOUS DISEASES, 183, pp. 680 - 680, http://dx.doi.org/10.1086/318546

Nannini EC, 2001, 'Interleukin-2 in clinical trials: Other factors to be considered (multiple letters)', Journal of Infectious Diseases, 183, pp. 679 - 680, http://dx.doi.org/10.1086/318544

Babiker AG; Darbyshire JH; Cooper DA; Hooker MH; Withnall R; Yeni P; Angarano G; Antunes F; Churchill D; Conway B; Flepp M; Lelekis M; Gatell J; Girard PM; Hemmer R; Lundgren J; Mijch A; Mulcahy F; Ristola M; Salzberger B; Sandström E; Staszewski S; Weber J; De Wit S; Aboulker JP; Emery S; Floridia M; Gartland M; Manion D; Popescu M; Schnittman S; Stek M; Verbiest W; Flandre P; Law M; Schade-Brittinger C; Walker S; Bucciardini R; Boukli N; Carey D; Gargalianos P; Mollerup D; Brun-Vezinet F; Loveday C; Seligmann M, 2001, 'An open-label randomized trial to evaluate different therapeutic strategies of combination therapy in HIV-1 infection: Design, rationale, and methods of the initio trial', Controlled Clinical Trials, 22, pp. 160 - 175, http://dx.doi.org/10.1016/S0197-2456(00)00123-9

Emery S; Bodrug S; Richardson BA; Giachetti C; Bott MA; Panteleeff D; Jagodzinski LL; Michael NL; Nduati R; Bwayo J; Kreiss JK; Overbaugh J, 2000, 'Evaluation of performance of the Gen-Probe human immunodeficiency virus type 1 viral load assay using primary subtype A, C, and D isolates from Kenya', JOURNAL OF CLINICAL MICROBIOLOGY, 38, pp. 2688 - 2695, http://dx.doi.org/10.1128/JCM.38.7.2688-2695.2000

Losso MH; Belloso WH; Emery S, 2000, 'A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4(+) cell counts >= 350/mm(3) (vol 181, pg 1614, 2000)', JOURNAL OF INFECTIOUS DISEASES, 181, pp. 2122 - 2122, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000087923900051&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Losso MH; Belloso WH; Emery S, 2000, 'Erratum: A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4⁺ cell counts ≥350/mm³ (Journal of Infectious Diseases (May 2000) 181 (1614-1621))', Journal of Infectious Diseases, 181, pp. 2122, http://dx.doi.org/10.1086/315531

Back to profile page